CMSC Monday, May 12 2008
CMSC Online



 
Home arrow CMSC Online arrow For MS Professionals arrow Presentations
PML: What MS-Treating Clinicians Need To Know Print E-mail
PML: What MS-Treating Clinicians Need To Know
Sponsored by the Postgraduate Institute for Medicine
Release date: December 2006

Expiration date: December 2007
Estimated time to complete activity: 1 hour

This educational program is supported through an educational grant from Biogen IDEC and Elan Pharmaceuticals Inc.

Program Overview
The reporting of progressive multifocal leukoencephalopathy (PML) in association with natalizumab therapy, leading to the temporary withdrawal from the market of this agent, makes education regarding this relatively unusual disease critical. This program will outline the current state of knowledge of PML and discuss the disease itself (both the primary disease and the phenomenon occurring secondary to reversible causes). The clinical manifestations of PML vs. MS, the association of PML with natalizumab and other immune modulators/suppressants, and the fact that there is no current treatment—save immune restoration—will also be covered.

Technical Requirements
Processor Speed: 1.4 GHz P3
Memory: 256 MB RAM (20 MB Available)
Operating Systems Supported: Windows 2000 / XP
Browsers Supported: Internet Explorer 5.5 or greater and Mozilla Firefox
Additional Requirements: Flash player 8.0 or greater 800x600 Resolution or Higher with 32-bit color
Connection Speed: 128 Kbps or better
Adobe Reader 6.0 or greater.

CME Information
Click here to review the complete CME information.